What is KromaTiD?
KromaTiD is at the forefront of genomic integrity analysis, providing critical single-cell data solutions for the biotechnology and pharmaceutical industries. Their proprietary KROMASURE platform offers deep insights into chromosomal integrity, structural variants, and transgene mapping. This technology is instrumental for clients focused on applications such as assessing insertional mutagenesis risk, conducting genotoxicity profiling, and optimizing gene edits. By ensuring genomic stability from discovery through commercialization, KromaTiD empowers clients to make data-driven decisions for developing safer and more effective therapies.
How much funding has KromaTiD raised?
KromaTiD has raised a total of $16.2M across 6 funding rounds:
Private Equity
$622K
Debt
$150K
Debt
$274K
Multiple Rounds
$15.1M
Private Equity (2016): $622K, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $274K supported by PPP
Private Equity (2025): $3.5M, investors not publicly disclosed
Private Equity (2025): $3.6M, investors not publicly disclosed
Series C (2025): $8M with participation from BroadOak Capital Partners
Key Investors in KromaTiD
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Since its inception in 2006, it has invested in over 70 companies and advised on more than 50 successful M&A transactions. The firm focuses on life sciences tools, diagnostics, and biopharma services, leveraging its in-house expertise and extensive networks to deliver exceptional results for its clients. BroadOak aims to provide growth capital and advisory services to help management teams optimize their business strategies.
What's next for KromaTiD?
The recent major strategic investment signals a strong validation of KromaTiD's technology and market position. This capital infusion is anticipated to fuel further innovation in their genomic analysis platforms and expand their reach within the rapidly growing cell and gene therapy market. KromaTiD is poised to play an increasingly vital role in regulatory compliance and therapeutic development, solidifying its importance in bringing advanced treatments to patients.
See full KromaTiD company page
